HMB-002 (Part A)

PreclinicalSmall molecule

HMB-002 (Part A) is one of 3 small molecule programs targeting Von Willebrand Disease (VWD). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand Disease (VWD)Recruiting

Von Willebrand Disease (VWD)Preclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Von Willebrand Disease (VWD)

#DrugCompanyPhaseTrials

VGA039

VVega Therapeutics, Inc

Phase 3

1 2

ALN-6400

Alnylam Pharmaceuticals

Phase 2

1 3

HMB-002 (Part A)

UUnknown Sponsor

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Von Willebrand Disease (VWD)

NCT06754852

Clinical

Trials by Indication[1]

Von Willebrand Disease (VWD)1 trial

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)

Recruiting·UUnknown Sponsor·Preclinical·NCT06754852·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HMB-002 (Part A). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HMB-002 (Part A) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HMB-002 (Part A). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUnknown Sponsor

HMB-002 (Part A)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Von Willebrand Disease (VWD)1 trial

References

Drug Info

Quick Facts

Related News